PECULIARITIES OF OF IMMUNOLOGICAL PARAMETERS IN PATIENTS WITH RECURRENT HERPES SIMPLEX VIRUS INFECTION
Introduction. Considering the importance of herpes simplex virus infection as one of the triggers in the development of systemic connective tissue diseases, studying and evaluating the eff ectiveness of antiviral treatment is an important issue in this group of patients.
Aim. The investigation of clinical effi cacy of antiviral therapy in patients with systemic connective tissue disease and chronic recurrent herpes during and after treatment and in the long term, depending on the therapy received.
Materials and methods. The study involved 59 patients who were treated at Lviv Regional Clinical Diagnostic Center and Lviv Regional Clinical Hospital - clinical centres of the Department of Clinical Immunology and Allergology of Danylo Halytsky Lviv National Medical University.
Results. Based on the data obtained, the clinical effi cacy of Inosine pranobex (Novirini) in groups of patients with mild, moderate and severe herpes simplex infection and systemic connective tissue disease was calculated. The results show that use of Inosine Pranobex in patients with a mild course HSV 1/2 infection contributed to headache relief in 82.4%, temperature normalization in 75.0%, and decreases fatigue in 72.2%. In the group of patients with moderate to severe herpes virus infection, who received Acyclovir in addition to Inosine Pranobex, headache was reduced in 73.9%, temperature normalization in 66.6%, fatigue reduction in 65.5% of cases.
Conclusion. The use of antiviral therapy in patients with systemic connective tissue disease and recurrent herpes simplex virus infection had a positive eff ect on patients' general condition, which was manifested by reduced intensity and frequency of headaches, the severity of fatigue and normalization of body temperature in all patients. Therefore, we can recommend antiviral therapy for this group of patients as part of the complex therapy involving an individual approach to each patient, which presupposes personalized treatment.
Vyhovska O.V. Herpes virus infections in children: classifi cation, clinical forms, manifestations, socio-medical aspects. Dutychyy likar. 2016; 4(49):41-51.
Su C, Zhang J, Zheng C. Herpes simplex virus 1 UL41 protein abrogates the antiviral activity of hZAP by degradingitsm RNA.Virol J. 2015; Dec 1;12:203.
Shmyha T.V., Hayevska V.Y., Hayevskyy V.Y. Features of the immune response in recurrent herpes virus infections of the fi rst and second types. Klinichna ta eksperymentalna patolohiya. 2017; Tom XVI, No1(59):190-194.
Su Chenhe, Zhan Guoqing, Zheng Chunfu. Evasion of host antiviral innate immunity by HSV-1, an update. Virology Journal. 2016;13:38. https://doi.org/10.12968/prtu.2016.53.38
Miranda-Saksena M., Denes E. C., Diefenbachand J. R., Сunningham L. A. Infection and Transport of Herpes Simplex Virus Type 1 in Neurons: Role of the Cytoskeleton. Viruses. 2018 Feb; 10(2): 92 https://doi.org/10.3390/v10020092
Belikova E.A., Ivanova G.F. Modern concepts of herpetic infection. Lakarstvennyy vestnik. 2015;3(59), tom 9:22-27.
You Yi, Wang Li, Yafei LI, Wang Qianqiu, Cao Shuanglin, Tu Yating [at all]. Multicenter randomized study of inosine pranobex versus acyclovir in the treatment of recurrent herpes labialis and recurrent herpes genitalis in Chinese patients. Journal of Dermatology. 2015;42:1-6.
Zlotnikova M. V., Novikova I. A. The mechanisms of natural and adaptive immunity in infections caused by herpes simplex viruses type 1 and 2 (lecture). Problemy zdorov'ya i ekologii. 2014:7-14.
Zhang Jie, Liu Huan, Wei Bin. Immune response of T cells during herpes simplex virus type 1 (HSV-1) infection. J Zhejiang UnivSci B. 2017 Apr.;18(4):277-288. https://doi.org/10.1631/jzus.B1600460
Murtaza M., Illzam Em., Muniandy Rk., Sharifah Am., Nang Mk., Ramesh B. Herpes simplex virus infections, Pathophysiology and Management. IOSR Journal of Dental and Medical Sciences. 2016;15(07):85-91. https://doi.org/10.9790/0853-150738591
Tognarelli I. E., Palomino F. T., Corrales N., Bueno M. S., Kalergis M. A., González1 A. P. Herpes Simplex Virus Evasion of Early Host Antiviral Responses. Frontiers in Cellular and Infection Microbiology.2019; Volume 9, Article 127:1-24.
Chopyak V.V. Lectures of clinical immunology and allergology for practitioners doctors. 2018;124-148.
Abstract views: 168 PDF Downloads: 82